Select Page
Responsive Centered YouTube Video
Consulting firm fined for opioid promotion, highlighting dangers of marketing mistakes in pharmaceutical industry.
  • Consulting firm McKinsey fined $230 million for US opioid settlements 0:06

  • Involvement in promotion and marketing of OxyContin led to the fine 0:25

  • FDA hearing discussed issues related to OxyContin at the time 0:33

  • Documentary series ‘Painkiller’ on Netflix provides insights into the opioid crisis 1:27

  • Warning about potential cancer explosion and autoimmunity concerns 1:54

  • Emphasis on understanding mechanisms like Faron, p53, and SV40 2:01

  • Importance of approaching medical research and interventions cautiously 3:04

Marketing strategy of OxyContin leading to addiction crisis and legal consequences.
  • Purdue Pharma settled for $230 million due to deceptive marketing of OxyContin. 4:02

  • OxyContin was aggressively promoted between 1996 and 2001, leading to widespread abuse. 4:40

  • FDA regulatory oversight was circumvented, allowing OxyContin to be marketed unchecked. 5:11

  • Sales of OxyContin grew significantly due to marketing efforts and aggressive promotion. 6:53

  • Aggressive marketing tactics included targeting prescribers and offering incentives. 7:13

  • OxyContin became a leading drug of abuse in the United States by 2004. 7:56

  • Purdue Pharma’s strategy involved identifying and promoting to prescribers already prescribing opioids. 8:14

Comparison between Covid vaccines and Oxycontin marketing, highlighting conflicts of interest and lack of targeted approach in vaccine distribution.
  • Sophisticated marketing campaign led to significant drug addictions with Oxycontin. 8:39

  • Governments promoted vaccines, but misinformation about transmission and pandemic control was not challenged. 9:05

  • Conflict of interest highlighted with FDA officials transitioning to pharmaceutical industry, raising concerns about regulatory decisions. 10:04

  • Issue with widespread vaccine rollout instead of targeted approach for high-risk populations. 12:05

Lessons on the risks of misrepresenting addiction and adverse events in marketing pharmaceuticals.
  • Misrepresentation of addiction risk in pharmaceutical marketing can have severe consequences. 12:24

  • Companies may downplay risks to certain patient cohorts, leading to adverse events. 12:35

  • Ongoing issues with misrepresentation of risks in pharmaceutical industry globally. 12:52

  • Purdue Pharma misrepresented addiction risk of OxyContin, leading to legal consequences. 13:00

  • Purdue Pharma faced criminal charges and fines for misbranding OxyContin. 14:59

  • Lessons learned on potential corruption and financial influence in pharmaceutical decision-making. 16:11

Lessons from past regulatory failure in applying therapies broadly, focusing on high-risk populations, and potential consequences of political influence and financial gain in the Covid-19 pandemic.
  • Regulatory failure due to one person’s influence and financial gain led to a major error affecting over 800,000 people in the US. 16:55

  • Applying therapies broadly without thorough understanding of the disease can be dangerous. 17:47

  • Focusing on high-risk populations is crucial to avoid risks associated with not treating or intervening. 18:05

  • Political influence and financial gain may have impacted the handling of the pandemic, leading to localized epidemics in highly vaccinated regions. 18:32

  • Africa’s approach with limited resources in managing the pandemic can provide valuable lessons. 19:07

  • Lessons from the pandemic may come at a significant cost and be painful. 19:16